As a result, developers using the OCELLOS platform for cellular orchestration will have more options for the ‘complex management’ required to manufacture CGTs.
“For many advanced therapy developers, scaling out from clinical trials and into commercialization requires more partners. Leveraging our expanded ecosystem allows OCELLOS users to advance without the need for bespoke systems requiring expensive, complex and difficult-to-manage integrations,” said Chris Came, VP relationship management at TrakCel.
“Working with OCELLOS means reassurance that as they grow, CGT developers will have the support needed for the vital work of bringing new life-saving medicines to patients.”
According to TrakCel, OCELLOS already includes the broadest choice of integrated supply chain partners in the industry, including partners for logistics, hub services, labelling, manufacturing execution systems (MES), enterprise resource planning (ERP) and contract research and manufacturing organizations.
TrakCel supports more than 25 CGTs with its platform at every step of clinical development, including many that have progressed through multiple stages to commercialization.
OCELLOS users can expect ‘full support’ from each integrated partner, which the company claims has been the case for existing collaborators such as Lonza, Cencora, QuickStat, Marken, Biocair, Körber, and Cardinal Health.
Each partner has a dedicated technical contract as well as a liaison for product development on hand, TrakCel added.
